DSIP

Intro

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide (sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, WAGGDASGE; molecular weight 849 Da) first isolated in 1977 from the cerebral venous blood of rabbits induced to sleep via thalamic electrical stimulation. It is found in human brain tissue (hypothalamus, limbic system, pituitary gland, frontal cortex), peripheral organs (pancreas, stomach, adrenal cortex, gonads), and — notably — in human breast milk, where its presence may partly explain why breastfed infants fall asleep readily post-feeding.

DSIP modulates delta-wave (slow-wave) sleep architecture directly, increasing the delta-wave activity that defines Stage 3 (N3) restorative sleep. This distinguishes it categorically from sedatives (which broadly suppress brain activity) and from melatonin (which shifts circadian phase). DSIP also modulates the hypothalamic-pituitary-adrenal (HPA) axis: it influences ACTH and cortisol secretion, LH release, and somatostatin expression. These HPA effects explain why DSIP shows the most consistent benefit in stress-related, HPA-dysregulation-driven insomnia — particularly the characteristic pattern of waking at 2-4 AM during the cortisol-surge window. Its effects are circadian-dependent: the compound biases sleep architecture during the biological night and does little during daytime.

Despite nearly 50 years of research, DSIP remains — in the words of a 2006 scientific review by Sudakov — 'a still unresolved riddle of neuroscience.' No gene, receptor, or precursor protein has been identified. Without a known receptor, standard drug-development pharmacology cannot be applied. Clinical research largely stopped in the mid-1990s, attributed to: no identifiable receptor, no patentable structure (naturally occurring peptide), and weak effects in the best-controlled trial (Bes et al. 1992, n=16, double-blind RCT, 3-night IV protocol). A 1988 meta-analysis concluded that effects in early trials were not significantly different from placebo when methodological biases were controlled.

Community interest has persisted and grown independently, driven by self-experimenters who find standard sleep interventions insufficient. DSIP occupies a specific niche: the sleep peptide for people who have tried everything else. The strongest field framing treats it as a circadian rhythm peptide that can affect sleep, not as a sleep drug. That lens explains both the distinctive responder profile and why it disappoints users expecting sedative-class effects.

Observed Effects

Responders report increased Stage 3 (slow-wave/delta-wave) sleep, fewer nighttime waking episodes (particularly early-morning waking associated with cortisol dysregulation), and waking feeling refreshed rather than groggy.

Vivid dreaming and enhanced dream recall is the single most consistently reported outcome — appearing in approximately 60-70% of positive experience reports, sometimes even in users who report no subjective improvement in sleep quality. Improvements in daytime alertness, cognitive performance, and stress tolerance were documented in Schneider-Helmert's clinical series.

In clinical trials (IV administration), sleep efficiency and shortened sleep latency reached statistical significance (Bes 1992, n=16) but subjective sleep quality did not improve significantly — a PSG-vs-subjective dissociation that may partly explain why some community users report objective improvement without perceiving it. Effects of a single IV dose lasted 6-20 hours. A series of 4 consecutive IV injections produced complete normalization of disturbed sleep in chronic insomniacs (Schneider-Helmert 1983).

Community responders describe a qualitative shift: 'A wholeness or peace — first felt within 48 hours, far more amplified 17 days in'; 'The static that's been running in my brain for years has quieted.' These descriptions are consistent with HPA normalization rather than pharmacological sedation. One community user tracking with a Garmin device reported a 10-point average sleep score improvement and +20 ms HRV increase on an every-other-night 400 mcg protocol. A separate long-term user (2+ years, nightly 160 mcg) reports sleeping through the night and dreaming nightly, with reversion to midnight waking when stopping — a return-to-baseline pattern rather than dependency.

Approximately 40% of community users report no perceptible effect. Null-responders describe 'feeling nothing' rather than adverse effects — a pattern distinct from GABAergic compounds where rebound insomnia is common. Null response is most frequent in users without HPA-dysregulation insomnia, users already running comprehensive sleep stacks, and users who may have received substandard product due to product-quality variability.

Field Reports

Responders describe a characteristic cluster of experiences: staying asleep longer, especially through the 2-4 AM window; waking more refreshed; more vivid and memorable dreaming; and a qualitative reduction in mental static or stress tone during waking hours. These descriptions repeat across independent user reports and practitioner anecdotes, suggesting a real signal in the responder population.

A long-term sustained-responder case describes 2+ years of nightly use around 160 mcg with sleeping through the night, only brief bathroom waking, nightly dreaming, no tolerance, no sedative effect, and a return to midnight waking when doses are missed. That return looks like recurrence of the original insomnia baseline rather than withdrawal.

Practitioner case reports describe DSIP helping some long-duration insomnia cases after failed zolpidem, eszopiclone, trazodone, melatonin, and CBT-I attempts. The useful interpretation is narrow: DSIP can act like a reset button when the reason for use matches its HPA/circadian profile, and can do little when the user expects a miracle sedative.

Stacking reports are mixed but informative. A 50-year-old TRT user in a multi-compound stack including Epithalon and tirzepatide reported entering deep sleep/dream state quickly and waking refreshed within 48 hours, with stronger effects by day 17; individual DSIP attribution is uncertain because the stack was not isolated.

One objective-tracking report on 400 mcg every other night described a 10-point average Garmin sleep score increase and +20 ms HRV improvement, while acknowledging possible placebo or coincidence.

Documented null responders are equally informative: one practitioner-educator found no benefit from 1,000 mcg over 20 days on top of a full sleep stack (GH + melatonin + 5-HTP + GABA + glycine); several users report DSIP, Epithalon, and sermorelin all failing for their specific complaint; another user found CJC (no DAC) + ipamorelin superior for their deep-sleep deficit; and one user ran three vials over 30 days with zero results. The null-responder pattern is usually feeling nothing rather than feeling worse.

Adverse experiences are limited but real: daytime somnolence at 100-150 mcg the following day in some users; persistent headache in at least two cases; and delayed next-day calming or sedation in at least two reports. None of these cases required medical intervention in the article's retained evidence.

Community Consensus

DSIP holds a specific niche in peptide communities: the sleep compound for users who have tried standard interventions and found them insufficient.

It appears rarely in general peptide discussion but prominently in chronic insomnia, sleep architecture, and failed pharmaceutical-sleep discussions. A 2024 analysis of 340 anecdotal reports across major peptide communities found roughly 60% of users described noticeable sleep improvements, while 40% reported no perceptible change; practitioner experience has reported a similar near-50/50 split.

The dominant community lens is that DSIP is a circadian rhythm peptide that can affect sleep, not a sleep drug. This explains both why DSIP works for some users (stress-driven, HPA-dysregulation insomnia) and why it fails for others (primary sleep-onset insomnia without HPA involvement; users expecting sedative-class effects).

The community-identified best-fit responder profile is stress-related insomnia, HPA axis dysregulation, waking at 2-4 AM during the cortisol-surge window, and sleep architecture problems rather than sleep-onset problems. Practitioner reports also describe better responses when insomnia is linked to stress and HPA dysregulation, with less reliable sleep induction in healthy individuals.

Epitalon is the most discussed stack partner — the combination is more consistently positive than DSIP monotherapy. The community interprets this as complementary circadian mechanisms: DSIP on delta-wave architecture, Epithalon on pineal melatonin output.

Product quality variability is cited consistently as a major driver of null responses. Community interpretation often treats third-party identity testing as the way to separate product failure from biological nonresponse. Cost (~$40-50/vial, ~$1-2/dose) makes DSIP accessible for extended experimentation.

Vivid dreaming and enhanced dream recall is the single most consistently documented positive outcome (60-70% of positive reports), sometimes occurring even in users who report no subjective sleep quality improvement — suggesting DSIP's REM architecture effects can dissociate from its slow-wave effects.

Community practice (100-300 mcg SubQ, every other night, 2-4 week courses) differs substantially from clinical trial protocols (25 nmol/kg IV, 3-10 consecutive nights). No controlled human study has evaluated subcutaneous DSIP. The community is self-experimenting with a route and schedule that has never been formally tested against a placebo.

Risks & Monitoring

A slight arousing or activating effect in the first 1-2 hours post-injection is the most consistently documented effect across clinical studies.

It resolves without intervention and represents DSIP's onset pattern rather than a true adverse effect — sleep-promoting benefits emerge in the second hour. All human clinical studies (n ranging from 6 to ~100 patients across diverse populations) described DSIP compatibility as 'good' with no significant adverse events.

In community practice, daytime somnolence the following day has been reported at 100-150 mcg SubQ in some users — an effect not documented in IV clinical trials, possibly reflecting delayed SubQ release kinetics or dose sensitivity. One community user at 100-150 mcg reported 'terribly sleepy all day and slight headache' and considered discontinuation. Headache has been reported in two community cases (one intranasal DMSO route, one SubQ); in one case the headache persisted for several days after cessation.

A 'time delay' phenomenon is documented by at least two community members: DSIP taken Monday, with the calming or sedating effect arriving Tuesday daytime rather than Monday night. The mechanism is uncertain but may reflect carrier-protein-bound DSIP being released slowly over 24+ hours after subcutaneous depot.

No dependency, tolerance, or rebound insomnia has been documented in any clinical study or community report. No effect on sex hormones (testosterone or estrogen) has been documented. No hepatotoxicity, nephrotoxicity, or organ toxicity has been reported. No post-cycle therapy is required. After stopping DSIP, sleep returns to its pre-use baseline.

For Women

Monitoring Panels

Avoid With

Protocols By Goal

Stress-related insomnia / HPA dysregulation (optimal use case): 100-200 mcg SubQ, 60-90 minutes before bed, 5 nights per week for a 14-day initial course.

If response is positive, reduce to every-other-night maintenance. Best candidates: waking at 2-4 AM during the cortisol-surge window, high chronic stress burden, adrenal activation during sleep. Stack with Epithalon (5-10 mg SubQ, same timing) for enhanced circadian normalization — the DSIP + Epithalon combination is more consistently positive than either compound alone.

GH secretagogue-induced sleep disruption: A meaningful proportion of ipamorelin, CJC-1295, and MK-677 users experiences persistent sleep architecture disruption through a non-cortisol mechanism. Protocol: add 100-200 mcg DSIP SubQ 1 hour before bed on GH secretagogue nights. DSIP does not appear to interfere with the GH pulse itself. Not all GH secretagogue users need this — only those experiencing actual sleep disruption from their GH protocol.

Chronic insomnia after failed pharmaceutical interventions (zolpidem, benzodiazepines, trazodone, melatonin, CBT-I): 10-14 day initial course at 100-200 mcg SubQ, 60 min before bed. Assess after completion; improvement may persist weeks to months. Re-dose with a second course if insomnia returns. The endpoint is waking more refreshed and fewer nighttime waking episodes — not faster sedation on demand.

Not recommended for: primary sleep-onset insomnia without HPA or stress component (lower response rate); users expecting on-demand sleep induction (DSIP cannot override a severely disrupted or absent circadian rhythm); users already running a comprehensive sleep stack (GH + melatonin + 5-HTP + GABA + glycine) — marginal incremental benefit is unlikely based on practitioner-educator personal experiment at 1,000 mcg over 20 days.

Dosing Details

Standard community protocol: 100-300 mcg subcutaneous, administered 60-120 minutes before intended sleep time, every other night or 2-3 nights per week.

The 1-2 hour pre-bed timing accounts for DSIP's documented onset pattern — slight arousal in hour 1, sleep benefit emerging in hour 2. Dosing immediately at bedtime may miss the observed window.

Starting dose: 50-100 mcg to assess individual response and tolerance to potential daytime somnolence before escalating. Titration to 200-300 mcg over several doses is reported when tolerated.

Cycle length: 10-30 days active use followed by a rest period. A 10-14 day consecutive course aligns with the clinical finding that 4 consecutive injections normalized sleep (Schneider-Helmert 1983); effects may persist 3-7 months after a 10-day course per clinical data. Some peptide-protocol references use longer 8-12 week courses at 5 nights per week with 2 nights off, but that schedule is not directly validated in controlled DSIP trials.

All human clinical trial data used IV administration at 25 nmol/kg (~1,500-1,750 mcg for a 70 kg person via slow IV infusion). Community SubQ protocols at 100-300 mcg extrapolate from IV findings without direct clinical validation — the route, absorption profile, and effective concentration achieved differ substantially.

Handling: community SubQ use depends on sterile peptide preparation, cold-chain discipline, and accurate concentration math. Those are operational details for qualified clinical or sterile-preparation contexts, not casual home-compounding instructions.

DSIP does not produce pharmacological tolerance per scientific literature. Community protocols using intermittent dosing are based on sensitivity preservation and cost efficiency rather than documented receptor downregulation.

Stacks & Alternatives

Complementary circadian mechanisms — the most documented and consistently positive DSIP combination. DSIP modulates delta-wave architecture directly; Epithalon restores pineal gland melatonin production via telomerase and epigenetic pathways (declining melatonin is a primary driver of sleep quality deterioration in aging). The two compounds act at different points in the circadian regulation chain. Community reports on DSIP + Epithalon are more consistently positive than either compound alone. Typical dosing: DSIP 100-200 mcg SubQ + Epithalon 5-10 mg SubQ, both 60-90 minutes before bed.

Addresses two distinct sleep disruption components. Selank gates sleep-onset anxiety (GABAergic + serotonin modulation); DSIP deepens architecture once sleep begins. For users whose insomnia has both an anxiety-onset component AND a cortisol/HPA-driven sleep quality component. Typical dosing: selank 100-300 mcg intranasal at bedtime + DSIP 100-200 mcg SubQ 60 min before bed. Documented in peptide community and protocol references.

Used when ipamorelin or CJC disrupts sleep quality in the user — a common pattern in a meaningful minority of GH secretagogue users. DSIP 100-200 mcg SubQ 1 hour before bed on GH secretagogue nights may counteract the architectural disruption while allowing the GH pulse to proceed. The GH secretagogue sleep disruption is not cortisol-mediated (persists beyond the cortisol adaptation period) and the mechanism is unknown.

Potentiation of GH pulse during slow-wave phases. Tesamorelin (GHRH analog) stimulates GH release; DSIP deepens the slow-wave sleep during which GH naturally pulses. Theoretical synergy: deeper slow-wave architecture = better GH pulse environment = enhanced anabolic/regenerative benefit. Documented in peptide protocol recommendations. Limited first-person reports.

Alternatives

Stack Cost

Practical Setup

DSIP is most likely to benefit users with stress-driven, HPA-dysregulation insomnia — characterized by early-morning waking at 2-4 AM, high chronic stress burden, and cortisol timing dysregulation.

Users with primary sleep-onset insomnia in a healthy circadian context, users already running comprehensive sleep stacks, and users expecting sedation-class effects are substantially less likely to respond.

Expectation management is the most important practical step: DSIP is not a sedative. It will not produce immediate drowsiness or unconsciousness. In a responder, the expected experience is: falling asleep in a more normal timeframe, staying asleep through the early-morning cortisol window, waking feeling more refreshed, and more vivid dreaming. The benefit may not be obvious on the first dose — circadian normalization is a cumulative process over 5-14 days.

Dose titration: start at 50-100 mcg SubQ to assess individual response, particularly sensitivity to daytime somnolence. Titrate up to 200-300 mcg over several doses if well tolerated. The time-delay phenomenon (effect arriving 24+ hours later) may be misread as null response on the first dose — allow several doses before concluding non-response.

Product-source selection is unusually important for DSIP. Community data attributes a meaningful proportion of null responses to substandard product rather than true pharmacological non-response. Treat third-party identity documentation as important context when interpreting null response.

Circadian dependence: DSIP cannot force sleep on demand if the underlying circadian rhythm is absent or severely disrupted. For acute on-demand sleep induction or for users with fundamentally irregular circadian schedules, melatonin or prescription alternatives are more appropriate.

DSIP does not affect sex hormones and requires no post-cycle therapy. After stopping, sleep returns to whatever baseline existed before use — no withdrawal, no rebound insomnia, no dose escalation required over time. Long-term use (2+ years nightly) has been documented without diminished response.

Mechanism Deep Dive

DSIP modulates delta-wave (slow-wave) sleep architecture by increasing the delta-wave activity that characterizes Stage 3 (N3) restorative sleep.

This is a direct architectural mechanism — distinct from sedatives (which induce unconsciousness via GABAergic or other CNS depression) and from melatonin (which shifts circadian phase rather than deepening architecture). The compound is bioidentical, distributed across the hypothalamus, limbic system, pituitary, and peripheral organs — a distribution profile consistent with its multi-system HPA and circadian effects.

HPA axis interactions: DSIP modulates ACTH and cortisol secretion (consistent with its efficacy in stress-driven insomnia characterized by premature cortisol surge), influences LH release (potential HPG-axis interaction unconfirmed in humans), and augments somatostatin expression (the hypothalamic GH-inhibiting hormone — a possible mechanism for DSIP's interaction with the GH-sleep axis). A practitioner-educator has noted DSIP 'touches the hypothalamus and pituitary, tweaks stress hormones like ACTH and cortisol, nudges LH and GH, and influences neurotransmitters tied to stress, mood, and pain.'

NMDA receptor hypothesis: DSIP may activate NMDA receptors (activated by glycine and glutamate), a pathway associated with relaxation, sedation, and neurological modulation. This is consistent with the clinical observation of mild improvement in sleep architecture without hypnosis.

Pharmacokinetics: IV plasma half-life approximately 7-8 minutes (ultra-short, due to rapid proteolytic cleavage starting with the tryptophan residue). Yet sleep-promoting effects persist 6-20 hours after a single injection — implying either a cascade mechanism or receptor-driven downstream signaling that outlasts the peptide itself. Endogenous DSIP circulates predominantly in a carrier-protein-bound form with a functional half-life of approximately 7-8 hours, which protects it from proteolysis. Subcutaneous pharmacokinetics are not formally characterized; the community-reported 'time delay' effect (sedating influence arriving 24+ hours after SubQ injection) may reflect slow release from a carrier-protein-bound depot. DSIP exhibits a U-shaped dose-response curve — at low doses it promotes sleep; at higher doses effects diminish or reverse. This has practical implications: community high-dose protocols (500-1,000 mcg) may produce less effect than moderate doses (100-300 mcg).

Circadian dependence: DSIP's effects depend on the presence of the biological night. It biases sleep architecture when that context is present but cannot create or override circadian rhythm. This fundamental constraint separates it from sedatives and positions it as a modulator of existing circadian architecture.

The central unresolved puzzle: no gene, receptor, or precursor protein has been identified despite nearly 50 years of research. The 2006 Sudakov review described DSIP as 'a still unresolved riddle of neuroscience' — an accurate characterization that remains true today. Without a known receptor, all mechanistic claims above rest on pharmacological observation rather than receptor pharmacology.

Evidence Index